CellPoint : Advancing Molecular Technology Metabolic Cancer Imaging and Therapeutic Targeting Through Nuclear Medicine - Cell Point

      home

      about us

      management

      board

      r & d

        pipeline

      EC Mechanism
      video
      news
      articles

      patents

      quarterly reports

      contact us

 
 


Click here for animation

 

  <  patents  >

Cell>Point is pursuing an aggressive domestic and international patent protection program for each of the licensed technologies. The Company's product development and clinical trial scheduling is geared toward preserving as much of the remaining patent life for each commercialized product as possible.  In every case, the owner of the patent (domestic or international) is the Board of Regents of The University of TexasM.D.AndersonCancerCenter.Cell>Point has full patent rights for life of patent.

 

The following is the patent issuance and application status of each of the technology platforms.

 

  1. Initial EC Technology U.S. patent   

      issued (US 6,692,724 B1)

  2. Second EC Technology U.S. patent

      issued (US 7,067,111)

  3. Third EC Technology U.S. patent application

       approved and awaiting issuance (App. No. 10/672,763)           

  4.  Fourth EC Technology U.S. patent

       approved and awaiting issuance (App. No. 10/672,142)

  5.  Fifth EC Technology U.S. patent application

       under examination (App. No. 11/405/334)

  6.  Sixth EC Technology U.S. patent application

       under examination (App. No. 10/732,919)

  7.  First Australia EC Technology patent issued (2001275210)

  8.  First China EC Technology patent issued (ZL 01811605.1)

  9.  All remaining domestic and international

       EC Technology patent applications are in various

       stages of review.

10.  In-Situ Hydrogel U.S. patent application approved

       and awaiting issuance (App. No. 10/024/678).

11.  All international In-Situ Hydrogel patent

       applications are pending and in various stages of review.

12.  Beta Cell Technology U.S. patent 

       application is under review (App. No. 10/942,615)

13.  Beta Cell Technology international

       applications are under review.

14.  Dual Agent Technology U.S. patent

       application under review (App. No. 11/326,117)

15.  N4 Technology U.S. provisional patent

       application filed September 2006

        (App. No. 60/745,148)

16.  N4 Technology international PCT

       Patent application filed September


Back to top

                                                                                                                                                                                                                                                                     

© copyright 2001-2007|Cell>Point L.L.C | all rights reserved | maintained by Link2City.com  

Terry Colip 

Home | About Us | Management Team | Scientific Advisory Board | Corporate fact Sheet
EC Mechanism of Action | Video |  R & D | Agents Pipeline | News | Articles | Patents | Corp Financials | Contact Us